X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20101) 20101
Book Review (3427) 3427
Publication (1833) 1833
Conference Proceeding (133) 133
Book Chapter (109) 109
Dissertation (44) 44
Magazine Article (29) 29
Web Resource (18) 18
Reference (6) 6
Book / eBook (5) 5
Government Document (5) 5
Paper (4) 4
Streaming Video (4) 4
Journal / eJournal (2) 2
Newspaper Article (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14602) 14602
humans (14144) 14144
imatinib mesylate (11769) 11769
imatinib (8550) 8550
oncology (6929) 6929
benzamides (6845) 6845
male (5922) 5922
female (5471) 5471
pyrimidines - therapeutic use (5119) 5119
piperazines - therapeutic use (4745) 4745
middle aged (4691) 4691
antineoplastic agents - therapeutic use (4666) 4666
hematology (4399) 4399
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (4219) 4219
adult (4092) 4092
chronic myelogenous leukemia (3768) 3768
chronic myeloid-leukemia (3672) 3672
aged (3536) 3536
chronic myeloid leukemia (3344) 3344
cancer (2944) 2944
animals (2619) 2619
pyrimidines - pharmacology (2618) 2618
treatment outcome (2613) 2613
protein kinase inhibitors - therapeutic use (2496) 2496
piperazines - pharmacology (2360) 2360
leukemia (2336) 2336
bcr-abl (2147) 2147
mutation (2071) 2071
therapy (2007) 2007
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1909) 1909
antineoplastic agents - pharmacology (1840) 1840
dasatinib (1829) 1829
protein-tyrosine kinases - antagonists & inhibitors (1789) 1789
tyrosine kinase inhibitor (1650) 1650
prognosis (1640) 1640
tyrosine kinase (1619) 1619
gastrointestinal stromal tumors (1598) 1598
care and treatment (1594) 1594
pyrimidines - administration & dosage (1547) 1547
mice (1540) 1540
fusion proteins, bcr-abl - genetics (1480) 1480
protein kinase inhibitors - pharmacology (1477) 1477
pharmacology & pharmacy (1467) 1467
hemic and lymphatic diseases (1459) 1459
research (1448) 1448
tumors (1444) 1444
gastrointestinal stromal tumors - drug therapy (1429) 1429
abridged index medicus (1423) 1423
tyrosine (1423) 1423
leukemia, myelogenous, chronic, bcr-abl positive - pathology (1422) 1422
aged, 80 and over (1417) 1417
cml (1413) 1413
piperazines - administration & dosage (1376) 1376
pyrimidines - adverse effects (1361) 1361
c-kit (1349) 1349
cell line, tumor (1331) 1331
resistance (1331) 1331
analysis (1320) 1320
drug resistance, neoplasm (1315) 1315
adolescent (1301) 1301
tyrosine kinase inhibitors (1291) 1291
medicine & public health (1264) 1264
antineoplastic agents (1245) 1245
apoptosis (1210) 1210
antineoplastic agents - adverse effects (1207) 1207
gist (1198) 1198
young adult (1194) 1194
chemotherapy (1170) 1170
expression (1158) 1158
nilotinib (1155) 1155
mesylate (1148) 1148
piperazines - adverse effects (1142) 1142
antimitotic agents (1112) 1112
antineoplastic agents - administration & dosage (1095) 1095
drug therapy (1091) 1091
gastrointestinal stromal tumors - pathology (1069) 1069
gastrointestinal stromal tumor (1055) 1055
diagnosis (1050) 1050
proto-oncogene proteins c-kit - genetics (1025) 1025
kinases (1013) 1013
surgery (1013) 1013
hematology, oncology and palliative medicine (1007) 1007
cell biology (999) 999
mutations (961) 961
survival (951) 951
genetic aspects (949) 949
kit (944) 944
retrospective studies (927) 927
apoptosis - drug effects (910) 910
health aspects (884) 884
neoplasms (869) 869
in-vitro (863) 863
philadelphia-chromosome (855) 855
article (853) 853
cells (843) 843
fusion proteins, bcr-abl - metabolism (821) 821
pathology (820) 820
biochemistry & molecular biology (800) 800
follow-up (786) 786
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (786) 786
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18402) 18402
Japanese (389) 389
French (349) 349
Chinese (306) 306
German (272) 272
Spanish (186) 186
Russian (77) 77
Polish (76) 76
Korean (72) 72
Czech (41) 41
Italian (36) 36
Portuguese (36) 36
Hungarian (33) 33
Turkish (26) 26
Danish (10) 10
Dutch (10) 10
Croatian (9) 9
Romanian (6) 6
Slovenian (6) 6
Swedish (5) 5
Slovak (4) 4
Ukrainian (4) 4
Finnish (3) 3
Hebrew (3) 3
Bulgarian (2) 2
Norwegian (2) 2
Persian (2) 2
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 660 - 662
Estimates suggest that nearly 30% of patients diagnosed with chronic myeloid leukemia (CML) are aged <49 years, with approximately half being women. For many... 
ONCOLOGY | IMATINIB
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 12/2017, Volume 31, Issue 12, pp. e519 - e521
Journal Article
Leukemia, ISSN 0887-6924, 07/2018, Volume 32, Issue 7, pp. 1657 - 1669
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | RANDOMIZED CML | ONCOLOGY | COMPLETE MOLECULAR REMISSION | LONG-TERM SURVIVAL | MANAGING CHILDREN | RECEIVING IMATINIB | DOSE IMATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EUROPEAN-LEUKEMIANET | Prognosis | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Imatinib Mesylate - therapeutic use | Neoplasm Grading | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Treatment Failure | Imatinib Mesylate - administration & dosage | Female | Child | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Treatment Outcome | Combined Modality Therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Bone Marrow - pathology | Adolescent | Biomarkers | Neoplasm Staging | Adolescence | Imatinib | Myeloid leukemia | Complications | Leukemia | Stem cell transplantation | Transplantation | Chronic myeloid leukemia | Survival | Patients | Molecular chains | Intolerance | Side effects | Failure analysis | Stem cells | Children | Adolescents | Index Medicus
Journal Article
10/2011
Background: Treatment of cancers with cytotoxic agents such as tyrosine kinase inhibiting drugs often, but not always, result in transient to permanent... 
Imatinib | testosterone | lactate dehydrogenase
Web Resource
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 16, pp. 2423 - 2433
Journal Article
Journal Article
Urology, ISSN 0090-4295, 07/2019, Volume 129, pp. 206 - 209
Dermtofibrosarcoma protuberans is a rare cutaneous malignancy known to be locally aggressive. It is uncommonly seen in the pediatric population and can be... 
UROLOGY & NEPHROLOGY | IMATINIB
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 25, pp. 2659 - 2660
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 01/2014, Volume 24, Issue 1, pp. 52 - 61
OBJECTIVEThe tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia are substrates for the efflux transport protein ATP-binding... 
CGP74588 | Imatinib | Pharmacogenetics | Tyrosine kinase inhibitor | Single-nucleotide polymorphism | Chronic myeloid leukemia | N-desmethyl imatinib | ABCG2 | LOCALIZATION | STEM-CELLS | PROTEIN | STANDARD-DOSE IMATINIB | imatinib | TRANSPORTER ABCG2 | P-GLYCOPROTEIN | RESPONSES | PHARMACOKINETICS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | RESISTANCE | chronic myeloid leukemia | PHARMACOLOGY & PHARMACY | PATIENTS RECEIVING IMATINIB | tyrosine kinase inhibitor | single-nucleotide polymorphism | pharmacogenetics | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Nitriles - pharmacology | Benzamides - pharmacokinetics | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Neoplasm Proteins - metabolism | Nitriles - pharmacokinetics | Quinolines - pharmacology | Thiazoles - pharmacokinetics | Genetic Variation | Quinolines - pharmacokinetics | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette Transporters - metabolism | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Membrane - metabolism | Piperazines - pharmacokinetics | Neoplasm Proteins - genetics | Protein Kinase Inhibitors - pharmacokinetics | Cell Line | Dasatinib | Aniline Compounds - pharmacology | Transduction, Genetic | Genotype | Aniline Compounds - pharmacokinetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | K562 Cells | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Mutation | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN | ABCG2; CGP74588; chronic myeloid leukemia; imatinib; N-desmethyl imatinib; pharmacogenetics; single-nucleotide polymorphism; tyrosine kinase inhibitor
Journal Article
01/2010
Imatinib is a clinically well-tolerated small molecule inhibitor that exerts selective, dual inhibition on the transforming growth factor beta and... 
Angle | imatinib | conformation
Web Resource
08/2012
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative expansion of primitive hematopoietic progenitor cells. Materials and Methods: In the... 
myeloid leukemia | Imatinib | philadelphia chromosome
Web Resource
Journal Article